Stock EXTX EXACT THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News EXACT Therapeutics

Equities

EXTX

NO0010852213

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-25 am EDT 		5-day change 1st Jan Change
6.8 NOK 0.00% Intraday chart for EXACT Therapeutics -2.86% -43.33%
Apr. 19 EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EXACT Therapeutics : Successful placement of NOK 25 million share issue
PU
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting
AQ
EXACT Therapeutics to Present at 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
EXACT Therapeutics AS - Share capital increase registered
AQ
EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14
AQ
EXACT Therapeutics : announces successful placement of NOK 25 million share issue
PU
EXACT Therapeutics AS: Primary insider notices
AQ
EXACT Therapeutics AS: Private placement successfully placed
AQ
EXACT Therapeutics AS: Contemplated Private Placement
AQ
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study
MT
EXACT Therapeutics receives regulatory approval to start recruitment of patients at Oslo University hospital
AQ
EXACT Therapeutics AS - Issuance of share options
AQ
EXACT Therapeutics CEO Dr Per Walday to participate in international Drug Delivery panel
AQ
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023
CI
EXACT Therapeutics : Interim Report 2023
PU
EXACT Therapeutics announces first half 2023 interim results
AQ
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development
AQ
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023
CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EXTX Stock
  4. News EXACT Therapeutics